[HTML][HTML] The full capacity of AICAR to reduce obesity-induced inflammation and insulin resistance requires myeloid SIRT1

Z Yang, X Wang, Y He, L Qi, L Yu, B Xue, H Shi - PLoS One, 2012 - journals.plos.org
Z Yang, X Wang, Y He, L Qi, L Yu, B Xue, H Shi
PLoS One, 2012journals.plos.org
Chronic Inflammation is a key link between obesity and insulin resistance. We previously
showed that two nutrient sensors AMP-activated protein kinase (AMPK) and SIRT1 interact
to regulate macrophage inflammation. AMPK is also a molecular target of 5-aminoimidazole-
4-carboxamide-1-β-D-ribofuranoside (AICAR), which has been shown to reduce insulin
resistance in various animal models. Here we aim to determine whether the therapeutic
effects of AICAR against insulin resistance involve its anti-inflammatory function, which …
Chronic Inflammation is a key link between obesity and insulin resistance. We previously showed that two nutrient sensors AMP-activated protein kinase (AMPK) and SIRT1 interact to regulate macrophage inflammation. AMPK is also a molecular target of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), which has been shown to reduce insulin resistance in various animal models. Here we aim to determine whether the therapeutic effects of AICAR against insulin resistance involve its anti-inflammatory function, which requires macrophage SIRT1. Long-term administration of low-dose AICAR significantly suppressed adipose inflammation in established diet-induced obese mice. This was associated with improved glucose homeostasis and insulin sensitivity without changes of body weight. In contrast, SIRT1 deletion in myeloid SIRT1 knockout (MSKO) mice increased infiltration of classically activated M1 macrophages and decreased alternatively activated M2 macrophages in adipose tissue. As a result, MSKO mice on high fat (HF) diets exhibited impaired insulin signaling in skeletal muscle, fat, and liver, and developed systemic insulin resistance in glucose tolerance tests, insulin tolerance tests, and hyperinsulinemic-euglycemic clamp experiments. Interestingly, the beneficial effects of AICAR on adipose inflammation and insulin sensitivity were absent in MSKO mice fed HF diets, suggesting that the full capacity of AICAR to antagonize obesity-induced inflammation and insulin resistance requires myeloid SIRT1. In summary, AICAR negatively regulates HF diet-induced inflammation, which requires myeloid SIRT1, thereby contributing to the protection against insulin resistance. Myeloid SIRT1 is a therapeutic target of the anti-inflammatory and insulin-sensitizing effects of AICAR.
PLOS